8-iso-prostaglandins for glaucoma therapy

Abstract

The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma It is based, at least in part, on the discovery that 8-iso prostaglandin E 2 effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.

1. A method for decreasing intraocular pressure comprising administering a therapeutically effective amount of an 8-iso prostanoid having the following Formula I: 
                   
       where bond W is selected from the group consisting of a single covalent bond and a double covalent bond, bond X is selected from the group consisting of a single covalent bond and a double bond, substituent Y is selected from the group consisting of a hydroxyl group having either α or β orientation relative to the five-membered ring and a keto function, and substituent Z is a hydrocarbon group selected from the group of aliphatic, aromatic, or a combination of aliphatic and aromatic hydrocarbon, to a patient in need of such treatment. 
     
     
       2. The method of  claim 1  wherein the 8-isoprostanoid is administered topically. 
     
     
       3. The method of  claim 2  wherein the 8-iso prostanoid is administered as a composition comprising between 0.005 to 1 percent 8-iso prostanoid. 
     
     
       4. The method of  claim 1 , wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula II 
                   
       or a derivative thereof. 
     
     
       5. The method of  claim 1 , wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula III 
                   
       or a derivative thereof. 
     
     
       6. The method of  claim 1 , wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula IV 
                   
       or a derivative thereof. 
     
     
       7. The method of  claim 2 , wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula II 
                   
       or a derivative thereof. 
     
     
       8. The method of  claim 2 , wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula III 
                   
       or a derivative thereof. 
     
     
       9. The method of  claim 2 , wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula IV 
                   
       or a derivative thereof. 
     
     
       10. The method of  claim 3 , wherein 8-iso prostanoid is selected from the group consisting of a compound having the following Formula II 
                   
       or a derivative thereof. 
     
     
       11. The method of  claim 3 , wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula III 
                   
       or a derivative thereof. 
     
     
       12. The method of  claim 3 , wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula IV 
                   
       or a derivative thereof. 
     
     
       13. The method of  claim 4 , wherein the derivative is an ester derivative. 
     
     
       14. The method of  claim 5 , wherein the derivative is an ester derivative. 
     
     
       15. The method of  claim 6 , wherein the derivative is an ester derivative. 
     
     
       16. The method of  claim 7 , wherein the derivative is an ester derivative. 
     
     
       17. The method of  claim 8 , wherein the derivative is an ester derivative. 
     
     
       18. The method of  claim 9 , wherein the derivative is an ester derivative. 
     
     
       19. The method of  claim 10 , wherein the derivative is an ester derivative. 
     
     
       20. The method of  claim 11 , wherein the derivative is an ester derivative. 
     
     
       21. The method of  claim 12 , wherein the derivative is an ester derivative. 
     
     
       22. A method for decreasing intraocular pressure comprising administering a therapeutically effective amount of an  8 - iso prostanoid having the following Formula I:                      
         where bond W is selected from the group consisting of a single covalent bond and a double covalent bond, bond X is selected from the group consisting of a single covalent bond and a double covalent bond and substituent Y is selected from the group consisting of a hydroxyl group having either α or β orientation relative to the five - membered ring and a keto function, to a patient in need of such treatment.    
     
     
       23. The method of  claim 22  wherein the  8 - iso prostanoid is administered topically.    
     
     
       24. The method of  claim 22  wherein the  8 - iso prostanoid is administered as a composition comprising between  0 . 005  to  1  percent  8   - iso prostanoid.